Malignant Hyperthermia: Clinical Management

Malignant hyperthermia is a subclinical myopathy in which general anesthesia triggers an uncontrollable contraction of skeletal muscle that leads to life-threatening hypercatabolic state and increase body temperature. The disease primarily autosomal dominant; mutations receptors (especially ryanodine receptor type 1) predispose volatile anesthetic agents or succinylcholine causing accumulation intracellular calcium its overactivation hypermetabolism. In the acute setting, diagnosis based mainly on clinical presentation end-tidal capnography, reveals CO2. Initial treatment measures include discontinuation agent reaction administration dantrolene. non-acute settings, there are specific diagnostic tools such as caffeine-halothane contracture test confirm suspected cases. MH lethal has high mortality rate if not treated early.